Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm: early-phase trial registry

1 of 1 indexed Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm: 1 US clinical trial tracked, 1 recruiting.

Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition recurrent-blastic-plasmacytoid-dendritic-cell-neoplasm

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Recurrent Blastic Plasma (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR Biological
1 trials
Bone Marrow Aspiration Procedure
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm trials. A trial with sites in several states counts in each.

Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Fred Hutchinson Cancer Center sponsors the most Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm condition card totals 1 registered trials; most-linked intervention CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.